Successful Refinancing: CHEPLAPHARM'S new 6.750% Bond multiple times oversubscribed

Greifswald, Germany, February 2, 2026

CHEPLAPHARM Arzneimittel GmbH ("CHEPLAPHARM"), a leading international pharmaceutical platform for established branded medicines, announces the successful placement of €950m of senior secured notes at an interest rate of 6.750%. The proceeds from the new notes will be used for the early redemption in full of two outstanding tranches of a bond maturing in 2028 totaling around €750m and for the partial repayment of a Term Loan B maturing in 2029. The transaction increases CHEPLAPHARM's financial flexibility and enables it to extend its maturity profile at attractive conditions.

The new bond met with high investor demand and was multiple times oversubscribed, enabling CHEPLAPHARM to increase the volume from originally planned €750m to €950m, while simultaneously reducing the coupon to 6.750%.

“In 2025, we made significant progress with our transformation program and noticeably stabilized our business development, thereby laying the foundation for this successful refinancing”, says Sebastian Braun, Co-CEO of CHEPLAPHARM. “The high demand for our new bond demonstrates the great confidence investors have in the path we have chosen. Now we must continue to consistently implement our transformation program and prepare CHEPLAPHARM for the next phase of growth.”

"I am very pleased about this successful capital market transaction, which allows us to redeem several outstanding tranches of a bond early and to extend our maturity profile on attractive terms", says Dr. Kia Parssanedjad, CFO of CHEPLAPHARM.

“Our new bond was multiple times oversubscribed, which enabled us to increase the volume by €200m, while simultaneously achieving a coupon of 6.750%. On behalf of the entire Management Board, I would like to once again express my sincere thanks to our existing and new investors for their support and trust.”

The new senior secured EUR notes mature in 2032. The Notes shall be issued on February 9, 2026, subject to customary closing conditions.

Citigroup and Deutsche Bank acted as Joint Global Coordinators and Bookrunners in the transaction. Joint Bookrunners were Barclays, BofA Securities, Commerzbank, Goldman Sachs, J.P. Morgan, ING, UBS Investment Bank, and UniCredit. On the legal side, CHEPLAPHARM was advised by Latham & Watkins, while Freshfields LLP was mandated as legal advisor to the banks.

About CHEPLAPHARM

CHEPLAPHARM is a family-owned company with headquarters in Greifswald. For over 20 years, the company has been very successful in taking over well-known and well-established medicines from the research-based pharmaceutical industry and transferring them to an existing global network of partners for production and distribution. In this way, CHEPLAPHARM ensures the continuous supply of these medicines to patients worldwide. In addition to its headquarters in Greifswald, CHEPLAPHARM operates further sites in France, Japan, Russia and Switzerland. The company employs around 800 people worldwide.

Please refer to www.cheplapharm.com for additional information.

CHEPLAPHARM Arzneimittel GmbH

Ziegelhof 24, 17489 Greifswald, Germany

CHEPLAPHARM Investor Relations:

Email: investor-relations@cheplapharm.com

CHEPLAPHARM Press Office:

Email: presse@cheplapharm.com

DISCLAIMER

This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.

The Notes and the related guarantees have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes and the related guarantees have been offered and sold (i) in the United States only to qualified institutional buyers in accordance with Rule 144A under the Securities Act and (ii) in “offshore transactions” to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act. There is no assurance that the issuance of the Notes will be completed or, if completed, as to the terms on which they will be completed.

The offer and sale of the Notes has been made pursuant to an exception under the Regulation (EU) 2017/1129 (the “Prospectus Regulation”) from the requirement to produce a prospectus for offers of securities. This press release does not constitute a prospectus within the meaning of the Prospectus Regulation or an offer to the public.

The distribution of this press release into certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

Forward-looking Statements

This news release may include “forward-looking statements” within the meaning of the securities laws of certain applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this news release, including, without limitation, those regarding Cheplapharm’s intentions, beliefs or current expectations concerning, among other things: Cheplapharm’s future financial conditions and performance, results of operations and liquidity; Cheplapharm’s strategy, plans, objectives, prospects, growth, goals and targets; future developments in the markets in which Cheplapharm participates or is seeking to participate; and anticipated regulatory changes in the industry in which Cheplapharm operates. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate”, “believe”, “continue”, “ongoing”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “target”, “seek” or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and that Cheplapharm’s actual financial condition, results of operations and cash flows, and the development of the industry in which Cheplapharm operates, may differ materially from (and be more negative).